Scholar Rock's Isembyld Approved by FDA for Spinal Muscular Atrophy

The FDA has approved Scholar Rock's apitegromab, marketed as Isembyld, for treating spinal muscular atrophy (SMA) in patients aged two and older who are also receiving SMN2-targeted treatment. This monoclonal antibody is the first muscle-targeted therapy for SMA, aiming to improve motor function for affected individuals.